Dyadic International (NASDAQ:DYAI) Shares Break Below 50 Day Moving Average – What’s Next?

Dyadic International Inc. (NASDAQ:DYAI)’s stock price passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $0.60 and traded as low as $0.4173. Dyadic International shares last traded at $0.4211, with a volume of 33,438 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Trading Down 3.6%

The stock has a market capitalization of $16.43 million, a PE ratio of -1.78 and a beta of 0.96. The stock has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.77.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%. The firm had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.02 million. Research analysts forecast that Dyadic International Inc. will post -0.15 earnings per share for the current year.

Institutional Trading of Dyadic International

An institutional investor recently bought a new stake in Dyadic International stock. BlackRock Inc. purchased a new position in shares of Dyadic International Inc. (NASDAQ:DYAI) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 197,749 shares of the biotechnology company’s stock, valued at approximately $177,000. BlackRock Inc. owned about 0.54% of Dyadic International at the end of the most recent reporting period. 27.95% of the stock is owned by institutional investors and hedge funds.

About Dyadic International

Dyadic International, Inc is a biotechnology company that develops microbial protein-production technologies for use in the biopharmaceutical, vaccine, industrial enzyme and food markets. Its platforms are designed to produce proteins efficiently at commercial scale, with potential applications including vaccines, therapeutic proteins, antibodies, enzymes and other biological products.

The company’s principal technology is its C1 expression platform, which uses a proprietary fungal host organism to produce recombinant proteins.